Pediatric Hematology Oncology Articles

FDA Grants Tisagenlecleucel Priority Review for DLBCL
The FDA has granted a priority review to the CAR T-cell therapy tisagenlecleucel for adult patients with relapsed/refractory DLBCL who are ineligible for or relapse after autologous stem cell transplant. 
TP53 Variants Increase Risk for Pediatric ALL, Adverse Treatment Outcomes
Children with TP53 pathogenic variants were more likely to both develop acute lymphoblastic leukemia, as well as secondary cancers later on, according to a recent analysis.
Lymph Node/LOH Status Predict Survival in Wilms Tumor
In patients with stage III favorable-histology Wilms tumor, negative nodal involvement and the absence of loss of heterozygosity at chromosomes 1p and 16q were predictors for event-free survival and overall survival.
Larotrectinib Rolling NDA Submission Initiated for TRK+ Cancers
Loxo Oncology has initiated a rolling submission of data for a NDA to the FDA for the novel pan-TRK inhibitor larotrectinib (LOXO-101) as a treatment for adult and pediatric patients with TRK fusion-positive advanced solid tumors.
Ipilimumab Approaches EU Approval for Pediatric Melanoma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of ipilimumab for the treatment of pediatric patients aged 12 years and older with unresectable or metastatic melanoma.
Triplet Shows Promise in Pediatric Kaposi Sarcoma
Investigators working in Malawi found an association between the combination of vincristine, bleomycin, and etoposide and improved quality of life, overall survival, and event-free survival in children with Kaposi sarcoma
Larotrectinib Achieves Over 90% Response in Pediatric Solid Tumors
The novel pan-TRK inhibitor larotrectinib (LOXO-101) achieved a 93% response rate in pediatric patients with TRK fusion–positive solid tumors. 
Proton Beam Therapy Safe, Effective in Pediatric Head and Neck Malignancies
Proton beam therapy in children and young adults with nonhematologic malignancies of the head and neck appeared to be safe and delivered local control rates similar to those seen historically.
Reduced GVHD Prophylaxis Possible in Pediatric Acute Leukemia
The risk for graft-vs-host disease is low in children aged 2 to 12 years with acute leukemia, suggesting these patients may be good candidates for reduced preventative measures.
Ipilimumab Effective in Adolescents With Advanced Melanoma
Ipilimumab was associated with a 1-year overall survival rate of 75% in adolescent patients with stage III/IV unresectable malignant melanoma.
Publication Bottom Border
Border Publication